Thursday, October 15, 2026
ExploreSearch
Finance Via News
Source trace. Via News points to the documents behind its reporting and shows what we drew from each — so you can check any claim. How we source
Source document· January 26, 2026

Directed Energy Weapons Research Report 2026: $32.53 Bn Market Opportunities, Trends, Competitive Landscape, Strategies, and Forecasts | Astute Analytica

View original at globenewswire.com
Directed Energy Weapons Research Report 2026: $32.53 Bn Market Opportunities, Trends, Competitive Landscape, Strategies, and Forecasts | Astute Analytica Chicago, Jan…
Opening lines of the source · short snapshot — read the full document at the original

What we drew from this source

The claims Via News extracted from this document. We point to the source; we don't replace it.

  • Japan has allocated $100 million to deploy 150 DEW systems over the next five years

    80% confidence

  • The global directed energy weapons market was valued at $7.11 billion in 2024 and is expected to reach $32.53 billion by 2033

    80% confidence

  • India's DURGA II initiative targets a 100-kilowatt laser weapon for deployment across land, sea, and air platforms

    80% confidence

  • The United States leads DEW development, allocating $2.3 billion in 2025 for research and development

    80% confidence

  • The DEW market is growing at a CAGR of 18.60% from 2025 to 2033

    80% confidence

  • High Energy Laser (HEL) technology captures more than 58% of the DEW market share

    80% confidence

  • Asia Pacific could contribute up to $32.1 billion of the global directed energy weapons market by 2033

    80% confidence

  • Lethal directed energy weapons account for more than 60% of the revenue share

    80% confidence

  • China follows with a $1.8 billion investment, primarily concentrating on high-power microwave weapons

    80% confidence

  • Russia's upgraded Peresvet laser system now boasts an engagement range of up to 10 kilometers

    80% confidence
What we know · the intelligence behind this page
Live from the substrate
What we're seeing
Q4 2026 Clinical Catalyst Season: Big-Pharma Data Flow, Regulatory Milestones, and a Thin AI-Drug Fringe
October 2026 conferences (EASD, IGCS, NACFC, HFSA) are producing a dense run of late-stage readouts from Novo Nordisk, Lilly, Roche, Bayer, Vertex and Galderma. Regulatory milestones are scheduled behind them: the ivonescimab BLA PDUFA date on 2026-11-14, FDA acceptance of Roche's vamikibart BLA, and Scholar Rock's EMA resubmission. The AI-and-finance angle is peripheral. It consists of the AI-designed drug Rentosertib and QAIAx, a speculative microcap whose trial claims (the QIII pilot, anticipated 2027-01-01, and a patent update) are forecasts and filings rather than data, so they warrant skepticism.
Our read on the data ›
Signals we're tracking
EPKINLY Regulatory-Clinical Success Cascade
High probability of expanded label indications, additional combination approvals, and competitive positioning strength in follicular lymphoma market. Predicts positive commercial uptake and potential accelerated review for related indications.
Patterns we're watching ›
Where sources disagree
ING Group
Both facts record the same metric (shares_outstanding) for ING Group at the identical observation date (2025-12-31). FACT A states 2,902,437,688 shares; FACT B states 2,902 million shares (2,902,000,000). The difference is 437,688 shares (~0.015%). This is a genuine value conflict, though the discrepancy appears to result from FACT B rounding to the nearest million while FACT A provides the precise count.
We flag conflicts openly ›
Recently verified
✓ Checked against the original source
4,986
facts traced to their source — and we flag the ones that don't hold up.
101 entities tracked4,986 facts checked against source5,375 source documents archived
Query this data → isubstrate.com
Directed Energy Weapons Research Report 2026: $32.53 Bn Market Opportunities, Trends, Competitive Landscape, Strategies, and Forecasts | Astute Analytica — Source | Via News | Finance Via News